Core Viewpoint - XuanZhu Biotechnology Co., Ltd. is undergoing a listing hearing on the Hong Kong Stock Exchange, with CICC as its sole sponsor [1] Company Overview - XuanZhu Biotechnology is an innovative Chinese biopharmaceutical company focused on improving patient health and addressing unique clinical needs in the Chinese pharmaceutical industry [4] - The company has established a comprehensive internal R&D platform since its acquisition by Sihuan Pharmaceutical Holdings Group in 2008, supporting a diverse and balanced pipeline [4] Product Pipeline - As of September 10, 2025, the company has over ten drug assets actively in development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [4] - The pipeline includes three core products: KBP-3571 (NDA approved for digestive system diseases), XZP-3287 (NDA approved for targeted breast cancer treatment), and XZP-3621 (NDA approved for targeted non-small cell lung cancer treatment) [4][6] Drug Development and Commercialization - The company has demonstrated exceptional speed and execution in drug development, having obtained a total of 20 IND approvals [5] - KBP-3571 has generated sales of RMB 32.7 million since its commercialization, indicating the company's capability in commercialization [6] - The company is expanding the indications for its core products and has several other oncology drug assets in various stages of clinical trials [7] Financial Performance - For the three months ending March 31 in 2023, 2024, and 2025, the company's revenues were RMB 29,000, RMB 30.094 million, and RMB 2.559 million, respectively [8] - R&D expenses for the same periods were approximately RMB 239.061 million, RMB 186.395 million, and RMB 53.044 million [8]
新股消息 | 轩竹生物通过港交所聆讯 首款获批产品KBP-3571已取得商业化收入
智通财经网·2025-09-17 23:23